Foster Victor Wealth Advisors LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 102.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 38,719 shares of the biopharmaceutical company’s stock after acquiring an additional 19,626 shares during the period. Foster Victor Wealth Advisors LLC’s holdings in Pfizer were worth $1,387,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the company. Signet Financial Management LLC increased its holdings in Pfizer by 0.4% during the fourth quarter. Signet Financial Management LLC now owns 71,686 shares of the biopharmaceutical company’s stock valued at $3,129,000 after buying an additional 292 shares during the period. Semmax Financial Advisors Inc. purchased a new position in Pfizer during the fourth quarter valued at approximately $585,000. Nomura Holdings Inc. increased its holdings in Pfizer by 1,854.2% during the fourth quarter. Nomura Holdings Inc. now owns 529,323 shares of the biopharmaceutical company’s stock valued at $22,956,000 after buying an additional 502,237 shares during the period. LMR Partners LLP purchased a new position in Pfizer during the fourth quarter valued at approximately $2,920,000. Finally, IHT Wealth Management LLC increased its holdings in Pfizer by 42.3% during the fourth quarter. IHT Wealth Management LLC now owns 48,934 shares of the biopharmaceutical company’s stock valued at $2,136,000 after buying an additional 14,554 shares during the period. 71.69% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on PFE shares. Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. JPMorgan Chase & Co. lifted their price objective on shares of Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a report on Tuesday, October 1st. Finally, ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Twelve research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $45.20.
NYSE PFE traded up $0.44 on Friday, hitting $36.23. The stock had a trading volume of 1,197,933 shares, compared to its average volume of 19,407,336. The business’s fifty day moving average price is $35.94 and its 200 day moving average price is $39.97. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $46.47. The stock has a market cap of $195.97 billion, a price-to-earnings ratio of 12.04, a price-to-earnings-growth ratio of 2.82 and a beta of 0.66.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. The firm had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.77 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.81 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.97%. The ex-dividend date is Thursday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
In related news, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the completion of the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: What is operating income?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.